TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31812464
Drug: IVACFLU-A/H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVACFLU-A/H5N1 vaccine (15 mcg)
Study: 30455160
Drug: Daily lottery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lottery incentives tied to achievement of weight loss goals
Study: 30455160
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of incentives and environmental strategies
Study: 24506910
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D supplementation (2000 IU/day)
Study: 24506910
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose vitamin D supplementation (400 IU/day)
Study: 22306855
Drug: HPV4 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV4 vaccine (standard schedule: 0, 2, 6 months)
Study: 22306855
Drug: HPV4 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV4 vaccine (modified schedule: 0, 3, 6 months)
Study: 29156321
Drug: Clear aligners
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear aligners treatment after 6 months
Study: 27619782
Drug: Mirabegron add-on
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron add-on treatment with tamsulosin
Study: 24428704
Drug: DS‐ALL treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS‐ALL treatment
Study: 24428704
Drug: Non-DS ALL
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-DS ALL treatment
Study: 22414766
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BI 207127 TID
Study: 22414766
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BI 207127 TID
Study: 22414766
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg BI 207127 TID
Study: 18837602
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with brief alcohol intervention (ST-BI)
Study: 11045266
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (ferrous sulfate 325 mg, 195 mg elemental iron, three times daily for 4 months)
Study: 11045266
Drug: Intravenous total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous total dose iron (ITDI) (1 g iron dextran mixed in 1/2 normal saline, single infusion over 4 hours for 4 months)
Study: 9299215
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg tablets
Study: 8420437
Drug: UK-74,505 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-74,505 (100 mg)
Study: 27821598
Drug: HOME BP
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HOME BP online digital intervention with self-monitoring, lifestyle advice and antihypertensive drug titration
Study: 22070357
Drug: Propranolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (up to 240 mg/day for 19 days)
Study: 19587388
Drug: CP‐690,550 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐690,550 5 mg twice daily
Study: 19587388
Drug: CP‐690,550 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐690,550 15 mg twice daily
Study: 19587388
Drug: CP‐690,550 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐690,550 30 mg twice daily
Study: 10347337
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 10 mg once a day)
Study: 10347337
Drug: Nitrendipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (5 to 10 mg once a day)
Study: 8942585
Drug: Large-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large-dose aprotinin (ALD)
Study: 8942585
Drug: Small-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small-dose aprotinin (ASD)
Study: 6189039
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment based on two cytostatic drug combinations (cyclophosphamide, adriamycin, vincristine, methotrexate, bleomycin, 5‐fluorouracil, procarbazine)
Study: 29930812
Drug: GSK2838232 (5-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (5-250 mg single doses, 20-200 mg repeat doses)
Study: 29930812
Drug: GSK2838232 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 with RTV (up to 200 mg once or twice daily)
Study: 29930812
Drug: GSK2838232 (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (50-100 mg without RTV, 50-250 mg with RTV)
Study: 29930812
Drug: Micronized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized formulation of GSK2838232
Study: 24703208
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid 1000 mg
Study: 19208703
Drug: Topical alkane
Normalized name: C12-19 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alkane vapocoolant spray (n=103)
Study: 19208703
Drug: Water spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water spray (control, n=98)
Study: 17324401
Drug: Capsule Endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Endoscopy (CE) followed by Push Enteroscopy (PE) if necessary
Study: 11680669
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rizatriptan (oral dose)
Study: 2666705
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with cardiac glycosides and vasodilators (2% nitroglycerin ointment, nitrosorbide or molsidomin)
Study: 31916662
Drug: Mid-treatment QIDS-4
Normalized name: Acne Treatment 4 % - 5 % Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-treatment QIDS-4
Study: 28057872
Drug: Etelcalcetide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide (5 mg initially, adjusted to 2.5-15 mg over 12 weeks)
Study: 25534580
Drug: Oscillating positive
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating positive expiratory pressure (PEP) device, thrice daily for 5 postoperative days
Study: 20945323
Drug: Romiplostim 750
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 750 μg administered subcutaneously weekly or biweekly
Study: 20945323
Drug: Romiplostim 750
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 750 μg administered biweekly intravenous injections
Study: 20945323
Drug: Weekly subcutaneous
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous injections
Study: 12654706
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg perindopril/0.625 mg indapamide
Study: 12654706
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily enalapril
Study: 8805730
Drug: Streptokinase (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1.5 million units intravenously in 100 mL of normal saline over 1 hour)
Study: 1385635
Drug: Triple antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antibiotics (ampicillin plus clindamycin plus gentamicin)
Study: 25943368
Drug: Deferiprone (DFP)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone (DFP) treatment for 6 to 12 months
Study: 25943368
Drug: Deferiprone (DFP)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone (DFP) treatment for 6 months
Study: 25943368
Drug: Deferiprone (DFP)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone (DFP) treatment
Study: 18246677
Drug: Acupuncture, Danshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, Danshen Zhushe Ye (Saliva Injection), and routine western drugs
Study: 7641716
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg initial dose, with repeat doses of 50 mg as needed up to 400 mg total
Study: 7641716
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg initial dose, with repeat doses of 5 mg as needed up to 40 mg total
Study: 2744062
Drug: Nitrendipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (mean final dose 55 mg/day)
Study: 23860021
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice capsules 600 mg twice a day for 8 weeks
Study: 20112482
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Baihui (GV 20), Fengchi (GB 20), Shuaigu (GB 8), Xingjian (LR 2), Neiguan (PC 6), Sanyinjiao (SP 6) combined with oral administration of Chinese herbal decoction
Study: 20112482
Drug: Simple oral
Normalized name: Simple Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oral administration of Chinese herbal decoction
Study: 17686346
Drug: Pharmaceutical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatments for fatigue in MS patients
Study: 17686346
Drug: Non-pharmaceutical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical treatments for fatigue in MS patients
Study: 12494285
Drug: Transdermal needle-free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal needle-free injection of alprostadil
Study: 12494285
Drug: Intracavernosal needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal needle injections of alprostadil
Study: 12494285
Drug: Needle-free injection
Normalized name: Stratis Needle-Free Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free injection
Study: 12494285
Drug: Needle-tipped injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-tipped injection
Study: 9819795
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Cytosine arabinoside (Ara‐C) (100 mg/m2/d, days 1‐7) and idarubicin (Ida) (12 mg/m2/d, days 1‐3) for induction; Ara‐C (200 mg/m2/d, days 1‐6) and Ida (15 mg/m2/d, day 1) twice for consolidation.
Study: 9819795
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Ara‐C (200 mg/m2/d, days 1‐10), daunorubicin (Dnc) (50 mg/m2/d, days 1, 3, 5) and etoposide (VP16) (100 mg/m2/d, days 1‐5) for induction; consolidation therapy with Ara‐C on days 1‐8 and additional regimens.
Study: 29175466
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 0.01% Methylene Blue and red laser, λ660 nm, 3J energy per point
Study: 29175466
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with λ660 nm, 1J energy per point
Study: 26966058
Drug: Tianjiu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianjiu therapy applied at three points (conception vessel 4, and bilateral kidney 1) during each HD session for 4 weeks.
Study: 26966058
Drug: Clay patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clay patches applied in the same way as those in the Tianjiu treatment group for 4 weeks.
Study: 26966058
Drug: Tianjiu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianjiu therapy
Study: 26966058
Drug: Clay patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clay patches
Study: 19926782
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/day for 6 weeks followed by 8 mg/day for 6 weeks)
Study: 7562885
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg for 1 month, 20 mg for 1 month, 40 mg for 4 months (once daily in the evening)
Study: 2196107
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with methotrexate, cisplatin, and continuous infusion 5-fluorouracil (MPF) (arm A)
Study: 2196107
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with bleomycin, cisplatin, and methotrexate (PBM) alternating with cisplatin and 5-FU (PF) (arm B)
Study: 23786763
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (ICBT) with MoodGYM
Study: 3528223
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg folic acid daily
Study: 29722833
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (2.3 g daily)
Study: 27168163
Drug: TRPV1 antagonist
Normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRPV1 antagonist ID1609
Study: 9114206
Drug: Sulbactam/cefoperazone (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/cefoperazone (2-4 g/d) administered in evenly divided doses every 12 hours by a 30-minute intravenous drip
Study: 9114206
Drug: Cefotaxime (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (6-12 g/d) administered in evenly divided doses every 6 or 8 hours by a 30-minute intravenous drip
Study: 30281805
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol (2 mg/d)
Study: 30281805
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (100 µg/d)
Study: 27765686
Drug: 10% sucralfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucralfate ointment (every 12 hours)
Study: 20049522
Drug: Non-woven textile
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-woven textile material (modified tampon) for vaginal drug delivery
Study: 12453372
Drug: Amoxicillin or
Normalized name: amoxicillin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin or clarithromycin (Group 2)
Study: 11188778
Drug: IVIG (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (intravenous immunoglobulin) 0.15-0.2 g/kg bodyweight monthly for 2 years
Study: 3326525
Drug: Ketoconazole 1200
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 1200 mg
Study: 3326525
Drug: Ketoconazole 1600
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 1600 mg
Study: 3326525
Drug: Ketoconazole (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (various doses)
Study: 31711306
Drug: Experimental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy (50% efficacious)
Study: 31711306
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (80% efficacious)
Study: 29659178
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of botanically sourced caffeine from 480 mg of green coffee bean extract
Study: 29659178
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of synthetic USP caffeine
Study: 20096510
Drug: Extended cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive behavioral treatment
Study: 12878335
Drug: Usual nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual nutritional rehabilitation program + 5 g x d(‐1) of spiruline
Study: 1858500
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied vaginal tablet of 150 mg econazole
Study: 1858500
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered capsule of 150 mg fluconazole
Study: 19942723
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional expectant treatment)
Study: 9834926
Drug: High-complex-carbohydrate, low-fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-complex-carbohydrate, low-fat formulation (HCF)
Study: 9834926
Drug: Low-carbohydrate formulation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate formulation (RCF)
Study: 24667592
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299 v (5 × 10 colony forming units daily)
Study: 27706045
Drug: Erythropoietin (33,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (33,000 IU IV daily for three days)
Study: 25342049
Drug: Meal 2
Normalized name: colloidal oatmeal 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal 2 (meal 1 mixed with 9 g guar)
Study: 18212755
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m² on days 1 and 8 every 3 weeks for three courses followed by docetaxel 37.5 mg/m² on days 1 and 8 every 3 weeks
Study: 4039588
Drug: Neobiphyllin (TPD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neobiphyllin (TPD) - 800 mg, infused for 20 min
Study: 4039588
Drug: Theophylline-ethylendiamine (TE)
Normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline-ethylendiamine (TE) - 480 mg, short-infusion for 20 min
Study: 27796434
Drug: Conventional hard‐shelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hard‐shelled gelatin capsule
Study: 25601917
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose unfractionated heparin (LDUH) 125 U/kg per day in three divided doses (Group B)
Study: 25601917
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) 6000 IU once a day (Group C)
Study: 25601917
Drug: LMWH 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH 4000 IU twice daily (Group D)
Study: 11245321
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotiam (study group, n=76)
Study: 9730793
Drug: MDPI (beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDPI (beclomethasone dipropionate) 400 microgram twice daily
Study: 9730793
Drug: MDI-spacer (beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-spacer (beclomethasone dipropionate) 400 microgram twice daily
Study: 8044729
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate depot injection used alone
Study: 22416440
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus ivabradin
Study: 15519705
Drug: Hib vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccination (1 dose)
Study: 15519705
Drug: Hib vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccination (2 doses)
Study: 15519705
Drug: Hib vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccination (3 doses)
Study: 10128359
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) administered in PVC containers
Study: 10128359
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) administered in glass containers
Study: 3310905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prochlorperazine, metoclopramide and dexamethasone
Study: 26840331
Drug: Resveratrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (200 mg/day)
Study: 24432995
Drug: Tianqi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianqi capsule for 12 months
Study: 23899039
Drug: Three-monthly monitoring
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly monitoring
Study: 19912490
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection (ICI) of alprostadil 20 microgram
Study: 16968572
Drug: Travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004% ophthalmic solution (Travatan)
Study: 11228598
Drug: 60% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% oxygen for ca. 10 min at 15 L/min by a face mask (treatment group)
Study: 9310010
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg isoniazid (INH)
Study: 9310010
Drug: 18.75 mg
Normalized name: carbidopa 18.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.75 mg isoniazid (INH)
Study: 23691692
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate maintenance infusion of 2 g/hour
Study: 23691692
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate maintenance infusion of 1 g/hour
Study: 19773098
Drug: Vero cell
Normalized name: Vero Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine without aluminum hydroxide adjuvant
Study: 19773098
Drug: Vero cell
Normalized name: Vero Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine with aluminum hydroxide adjuvant
Study: 19773098
Drug: Vero cell
Normalized name: Vero Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine
Study: 17522559
Drug: Intramuscular aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular aripiprazole (second injection)